IPRIPR2022-00739Final Written Decision
Eli Lilly and Companyv.Teva Pharmaceuticals International GmbH et al.
IPR challenge of US 11028161.
Type
IPR
Filed
Mar 23, 2022
Instituted
Sep 27, 2022
Decided
Sep 25, 2023
Patent
Application
17076772
Inventor
Marcelo Bigal et al
Granted
Jun 8, 2021
01
Timeline
3 milestones
2022-03-23Petition filed
2022-09-27Institution
2023-09-25Terminated
02
Parties & counsel
Petitioner
Eli Lilly and Company
Counsel
Feldstein, Market al
Patent Owner
Teva Pharmaceuticals International GmbH et al.
Counsel
Ellison, Eldoraet al
03
Docket
Documents are mirrored from the PTAB e-file system. Filer is as stated on the face of the filing.
SOURCE · USPTO PTAB E2EView on Unified Patents →